JAX strives to advance rare disease research and treatment options

For the past six years, the JAX Rare Disease Translational Center has worked with dozens of rare disease foundations to create custom mouse models that represent rare medical conditions, the majority of which present in young children.

In May 2022, JAX appointed Cathleen (Cat) Lutz, Ph.D., M.B.A. as Vice President of the Rare Disease Translational Center, marking an important step forward in its commitment to rare disease research. The expansion positions the Center to play an integral role throughout the entire rare disease odyssey, from diagnosis to research to drug development. The Center also collaborates closely with biotech and pharmaceutical companies to accelerate the path to drug discovery for these debilitating conditions. By taking a more holistic approach, the Center will make a significant impact on the experience of those living with rare diseases. Read more

Related Posts

Business Leaders: Deborah Bronk steers Bigelow Lab expansion to boost reach, programming

Deborah Bronk is president, CEO and a senior research scientist at Bigelow Laboratory for Ocean Sciences in East Boothbay, which will...

24 March 2025

UNE retains R2 Research status, reinforcing leadership in scientific advancement

The University of New England has retained its status as one of the country’s leading research universities with the recent release...

23 March 2025

Maine college students investigate health effects of forever chemicals

Two dozen Maine college students are investigating the public health effects of forever chemicals by using zebrafish as human stand-ins and...

21 March 2025